Paul Anthony Williams sold $20k of EBS
SVP, Products Business at Emergent BioSolutions Inc.. 3,000 shares at an average of $6.53, traded Oct 1, 2026, filed Oct 5, 2026.
Score components
- +15RoleOfficer
- 0Trade size$20k at market
- 0Share of holdings soldSold 1.9% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001961994-26-000029, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -3,000 | $6.53 | $20k | 156,098 | 8 d ago |
Related signals
Other insiders at Emergent BioSolutions Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $126k 17,800 shares | -14% | |
| 25Weak | Emergent BioSolutions Inc. | Sujata Tyagi Dayal director | $116k 13,761 shares | -12% | |
| 26Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $130k 15,481 shares | -11% | |
| 26Weak | Emergent BioSolutions Inc. | Keith Katkin director | $128k 15,481 shares | -14% | |
| 26Weak | Emergent BioSolutions Inc. | Kathryn C Zoon director | $144k 17,202 shares | -18% | |
| 1Weak | Emergent BioSolutions Inc. | Paul Anthony Williams SVP, Products Business | $34k 4,000 shares | -6% | |
| 18Weak | EBSsell Emergent BioSolutions Inc. | Ronald Richard director | $263k 21,984 shares | -21% | |
| 20Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $188k 17,801 shares | -13% | |
| 12Weak | Emergent BioSolutions Inc. | Sujata Tyagi Dayal director | $86k 8,552 shares | -9% | |
| 14Weak | Emergent BioSolutions Inc. | Coleen Glessner EVP, Quality & Ethics, and CPL | $306k 30,608 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.